相关实验视频
Updated: Aug 6, 2026
10:30
A Piglet Model of Neonatal Hypoxic-Ischemic Encephalopathy
Published on: May 16, 2015
19.7K
预测Gentamicin药理动力学模型在患有围产期窒息的新生儿中进行的预测性表现,这些新生儿接受控制的治疗性低温
Marlotte A A van der Veer1, Timo R de Haan2, Linda G W Franken1
1Department of Pharmacy & Clinical Pharmacology, Amsterdam University Medical Center, Amsterdam, the Netherlands.
Therapeutic drug monitoring
|January 30, 2024
概括
这项研究在接受治疗性低温症的新生儿中验证了一种珍塔米辛的药理动力学模型. 该模型准确地预测了药物水平,支持其用于为这个脆弱人群准确剂量.
科学领域:
- 药理动力学和药理动力学
- 新生儿医学 新生儿医学
- 治疗性低温症 治疗性低温症
背景情况:
- 种群药动力学 (PK) 模型对于开发剂量算法和精确剂量至关重要.
- 一个先前开发的 gentamicin PK 模型用于治疗性低温 (TH) 期间患有围产期窒息的新生儿,显示清除发生变化.
- 这项研究旨在验证该模型的预测性能和通用性.
研究的目的:
- 在治疗性低温下经历围产期窒息的新生儿中对 gentamicin 的种群药理学模型进行外部验证.
- 用独立的数据集评估模型的预测性能和通用性.
- 确认模型适用于基于模型的精确剂量.
主要方法:
- 使用来自PharmaCool研究的独立数据集进行验证.
- 通过观察与预测度图,偏差和精确计算来评估预测性能.
- 采用基于模拟的诊断,模型改造和引导分析,以进行可靠的评估.
主要成果:
- 外部数据集包括来自39名新生儿的323个 جنت胺度.
- 最初的珍塔素PK模型在TH期间预测度时表现出足够的准确性和精确性.
- 通过预测纠正的视觉预测检查和规范预测分布错误分析来确认模型的适当性.
结论:
- 外部验证证实了 gentamicin PK 模型对于TH期间患有围产期窒息的新生儿的概括性.
- 该模型支持之前推的 جنت米辛剂量方案 (根据妊娠年龄根据每36小时或每24小时服用5毫克/公斤).
- 经过验证的模型适用于在这个患者群体中以模型为基础的精确剂量.
相关概念视频
01:15Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).